Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
P Kardos, S Worsley, D Singh… - … journal of chronic …, 2016 - Taylor & Francis
Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …
and their combination are recommended for the maintenance treatment of chronic …
Correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD: a bayesian network meta-analysis of …
J Wu, Y Ye, C Li, W Zhou, R Chang - Journal of Cardiovascular …, 2019 - journals.lww.com
A majority of existing studies have focused on the efficacy of inhaled long-acting
bronchodilators (ILABs), such as long-acting muscarinic antagonists (LAMAs) and long …
bronchodilators (ILABs), such as long-acting muscarinic antagonists (LAMAs) and long …
LABA/LAMA as first-line therapy for COPD: a summary of the evidence and guideline recommendations
M Miravitlles, T Kawayama, M Dreher - Journal of Clinical Medicine, 2022 - mdpi.com
Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …
symptomatic patients with COPD, either as initial/first-line treatment or for second …
Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 …
C Li, W Cheng, J Guo, W Guan - International Journal of Chronic …, 2019 - Taylor & Francis
Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2–agonists
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
P Rogliani, MG Matera, J Ora, M Cazzola… - International journal of …, 2017 - Taylor & Francis
Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed …
Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
[PDF][PDF] Optimal bronchodilation for COPD patients: are all long-acting β2-agonist/long-acting muscarinic antagonists the same?
M Miravitlles, S Baek, V Vithlani… - … and respiratory diseases, 2018 - synapse.koreamed.org
Bronchodilators provide improvements in lung function and reductions in symptoms and
exacerbations, and are the mainstay of pharmacological management of chronic obstructive …
exacerbations, and are the mainstay of pharmacological management of chronic obstructive …
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta …
M Yang, Y Li, Y Jiang, S Guo, JQ He… - European Respiratory …, 2023 - Eur Respiratory Soc
Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …
Comparative cardiovascular and cerebrovascular safety of inhaled long‐acting bronchodilators in patients with chronic obstructive pulmonary disease: a population …
Study Objective Inhaled long‐acting bronchodilators are commonly used as maintenance
therapy in chronic obstructive pulmonary disease (COPD). We compared the risk of …
therapy in chronic obstructive pulmonary disease (COPD). We compared the risk of …
Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
NS Skolnik, TS Nguyen, A Shrestha, R Ray… - Postgraduate …, 2020 - Taylor & Francis
Long-acting inhaled bronchodilator medications are recommended as initial maintenance
therapy for many patients with COPD. These medications include long-acting muscarinic …
therapy for many patients with COPD. These medications include long-acting muscarinic …
相关搜索
- bronchodilator therapy cardiovascular safety
- dual bronchodilator therapy in copd
- combination therapy patients with copd
- muscarinic antagonists β2 agonist
- inhaled long acting bronchodilators
- combination therapy meta analysis
- muscarinic antagonists copd patients
- β2 agonist copd patients
- acting bronchodilators cerebrovascular safety
- meta analysis patients with copd
- optimal bronchodilation copd patients
- mortality in copd dual bronchodilation
- cardiovascular outcomes stable copd
- quantitative synthesis dual bronchodilation
- bayesian network stable copd
- bronchodilator therapy safety considerations